# NCT03952585 (NCT03952585)

> De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03952585
- Phase: PHASE2, PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Basaloid Squamous Cell Carcinoma; Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Oropharyngeal Squamous Cell Carcinoma; Papillary Squamous Cell Carcinoma; Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Squamous Cell Carcinoma
- Interventions: Biopsy Procedure; Biospecimen Collection; Cisplatin; Computed Tomography; Fludeoxyglucose F-18; Image Guided Radiation Therapy; Intensity-Modulated Radiation Therapy; Magnetic Resonance Imaging; Nivolumab; Positron Emission Tomography; Quality-of-Life Assessment; Questionnaire Administration
- Enrollment: 384
- Primary outcome: Progression-free Survival (PFS) (Phase II) (Percentage of Participants Alive Without Progression)
- Primary outcome: Progression-free Survival (Phase III) (Percentage of Participants Alive Without Progression)
- Primary outcome: MD Anderson Dysphagia Inventory (MDADI) Global Quality of Life (QOL) Score

## Commentary we found

- X threads: 10
- Podcasts: 4
- YouTube: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct03952585

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03952585", "email": "<work email>"}; the inbox owner confirms by the emailed link.